Headlines about Alnylam Pharmaceuticals (NASDAQ:ALNY) have trended somewhat positive on Sunday, Accern Sentiment reports. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Alnylam Pharmaceuticals earned a daily sentiment score of 0.18 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 46.1329018041587 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the headlines that may have effected Accern’s rankings:
- Alnylam Pharmaceuticals (ALNY) Given New $154.00 Price Target at Credit Suisse Group (americanbankingnews.com)
- Alnylam Pharmaceuticals, Inc. (ALNY) Insider Sells $12,672,077.40 in Stock (americanbankingnews.com)
- Alnylam Pharmaceuticals, Inc. (ALNY) President Sells $5,503,626.00 in Stock (americanbankingnews.com)
- Mad as a hATTR? Akcea, Ionis $1.7B tie-up queried (bioworld.com)
- Notable Hot Stock’s Alert: Altice USA, Inc., (NYSE: ATUS), Alnylam … – TNN (tradingnewsnow.com)
Shares of ALNY stock traded up $3.68 during trading hours on Friday, reaching $145.06. 1,444,004 shares of the company’s stock traded hands, compared to its average volume of 683,987. Alnylam Pharmaceuticals has a 1 year low of $46.90 and a 1 year high of $152.75. The company has a debt-to-equity ratio of 0.02, a current ratio of 12.23 and a quick ratio of 12.23. The company has a market capitalization of $14,486.85, a P/E ratio of -26.81 and a beta of 2.67.
A number of brokerages have weighed in on ALNY. BidaskClub raised shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday. Credit Suisse Group boosted their price target on shares of Alnylam Pharmaceuticals from $151.00 to $154.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 13th. Piper Jaffray Companies reissued a “buy” rating and set a $182.00 price target on shares of Alnylam Pharmaceuticals in a research note on Sunday, January 7th. Jefferies Group set a $156.00 price target on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, February 9th. Finally, BMO Capital Markets dropped their price target on shares of Alnylam Pharmaceuticals from $165.00 to $160.00 and set an “outperform” rating for the company in a research note on Friday, February 9th. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $126.89.
In other news, SVP Laurie Keating sold 6,249 shares of the company’s stock in a transaction that occurred on Wednesday, December 20th. The shares were sold at an average price of $121.20, for a total value of $757,378.80. Following the completion of the transaction, the senior vice president now owns 17,749 shares in the company, valued at $2,151,178.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, President Barry E. Greene sold 38,460 shares of the company’s stock in a transaction that occurred on Wednesday, March 14th. The shares were sold at an average price of $143.10, for a total transaction of $5,503,626.00. Following the completion of the transaction, the president now owns 97,544 shares of the company’s stock, valued at approximately $13,958,546.40. The disclosure for this sale can be found here. Insiders sold 232,831 shares of company stock valued at $32,776,807 in the last quarter. Corporate insiders own 4.30% of the company’s stock.
WARNING: “Alnylam Pharmaceuticals (NASDAQ:ALNY) Earning Somewhat Favorable Press Coverage, Study Finds” was originally published by BBNS and is the sole property of of BBNS. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://baseballnewssource.com/2018/03/18/alnylam-pharmaceuticals-alny-earns-news-impact-rating-of-0-18/2012423.html.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.